ClinicalTrials.gg
RecruitingNCT06052332SHAPERSUpdated Aug 3, 2026

Efficacy and Safety of Conventional Neoadjuvant Therapy Versus Total Neoadjuvant Therapy in Older Patients With Locally Advanced Rectal Cancer

An interventional study of Short course radiotherapy and Adjuvant chemotherapy (optional) in Locally Advanced Rectal Cancer and Older People, sponsored by Jules Bordet Institute. Recruiting at 19 sites in Belgium. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Jules Bordet Institute · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 56 studies in Rectal Neoplasms with a site in Belgium — 10 open to participants now, 20 under way, 4 of them phase 3. Rectal Neoplasms · Belgium.

Planned enrollment
19th of 45
230 · median 156
Started
2024
with 5 others
No phase
13 of 56
5 open now
Primary completion
2029-12
later than 16 of 19 live
Registered
48th of 56
by date
Lead sponsor
3 of 56
Jules Bordet Institute

Among the 56 studies in Rectal Neoplasms with a site in Belgium, this one is the 19th largest by planned enrollment of the 45 interventional ones that give a count, is one of 6 that started in 2024, is one of 13 with no phase, reaches primary completion later than 16 of the 19 other live ones, and was the 48th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

10 of the 56 studies in Rectal Neoplasms with a site in Belgium are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Rectal Neoplasms with a site in Belgium, or all of them as a file.
02

Study summary

The SHAPERS study is a multicentre, open-label, randomised, pragmatic clinical trial, comparing standard-of-care neoadjuvant treatment options for older (i.e., ≥70 years) subjects with high-risk stage II and stage III rectal cancer.

Read the detailed description

The SHAPERS study is a multicentre, open-label, randomised, pragmatic clinical trial, comparing standard-of-care neoadjuvant treatment options for older (i.e., ≥70 years) subjects with high-risk stage II and stage III rectal cancer.

Subjects meeting all eligibility criteria will be randomised in a 1:1 ratio to either the conventional arm or the TNT arm (The study design is shown in figure 3.1 and 3.2).

Conventional arm consists of:

  • SCRT (5 fractions of 5 Gy), followed by
  • Surgery (according to the principles of TME) or watch \& wait, followed by
  • Optional adjuvant chemotherapy OR
  • LCCRT (25-28 fractions of 1.8-2.0 Gy each +/- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion fluorouracil or capecitabine) followed by
  • Surgery (according to the principles of TME) or watch \& wait, followed by
  • Optional adjuvant chemotherapy

TNT arm Different treatment regimens can be used in the TNT arm including Rapido, Rapido light, OPRA INCT-CRT or OPRA CRT-CNCT. The regimen to use will be decided by the investigator and will need to be declared before randomisation. No switch between regimens is allowed during the study treatment period.

The Rapido regimen consists of:

  • SCRT (5 fractions of 5 Gy), followed by
  • Up to 18 weeks of oxaliplatin based chemotherapy (mFOLFOX6 or CAPOX), followed by
  • Surgery (according to the principle of TME) or "watch \& wait".

The Rapido light regimen consists of:

  • SCRT (5 fractions of 5 Gy), followed by
  • Up to 12 weeks of oxaliplatin based chemotherapy (mFOLFOX6 or CAPOX), followed by
  • Surgery (according to the principle of TME) or "watch \& wait".

The OPRA with induction chemotherapy (INCT-CRT) regimen, consists of:

  • Up to 16 weeks of oxaliplatin-based chemotherapy (mFOLFOX6 or CAPOX), followed by
  • CRT (25-28 fractions of 1.8-2.0 Gy each +/- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion fluorouracil or capecitabine) followed by
  • Surgery (according to the principle of TME) or "watch \& wait"

The OPRA with consolidation chemotherapy (CRT-CNCT) regimen consists of:

  • CRT (25-28 fractions of 1.8-2.0 Gy each +/- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion fluorouracil or capecitabine) followed by
  • Up to 16 weeks of oxaliplatin-based chemotherapy (mFOLFOX6 or CAPOX), followed by
  • Surgery (according to the principle of TME) or "watch \& wait".
03

Conditions studied

  • Locally Advanced Rectal Cancer
  • Older People

Browse trials for

Keywords

  • rectal cancer
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 70 years old
  2. performance status (PS):

    • ≤1 if age > 75 years old
    • ≤2 if age ≤ 75 years old
  3. or cytologically confirmed adenocarcinoma of the rectum
  4. Distal border of the tumour below the peritoneal reflection and within 15 cm of the anal verge
  5. Operable stage III or high-risk stage II rectal cancer (high-risk tumours defined as those having ≥1 of the following features: T4, mesorectal fascia (MRF) involvement/threatening [i.e.,tumour within 1 mm of the MRF], extramural venous invasion). Patient with involvement of lateral pelvic lymph nodes are also eligible.
  6. Adequate bone marrow function as defined below:

    • ≥1,500/µL
    • ≥9 g/dL
    • ≥100,000/µL
  7. Adequate liver function as defined below:

    • Serum total ≤1.5 x . In case of known Gilbert's syndrome \<3xUNL is allowed
    • (SGOT) and ALT (SGPT) ≤2.5 x ULN
    • Alkaline phosphatase ≤2.5 x ULN
  8. Adequate renal function as defined by estimated (GFR) ≥30 mL/min/1.73m² (according to the CKD-EPI 2021 equation).
  9. Absence of clinical conditions that in the opinion of the investigator, would contraindicate therapy and/or surgery.
  10. Signed form (ICF) obtained prior to any study related procedure.
  11. Male subjects with partners of must agree to use condom during the course of this study and for at least 6 months after the last administration of study drugs.

Exclusion criteria

Exclusion Criteria:

  1. Extensive growth into cranial part of the sacrum (above S2/3 junction) or the lumbosacral nerve roots indicating that surgery will never be possible even if substantial tumour down-sizing is achieved.
  2. Presence of disease or recurrent rectal tumour.
  3. Presence of grade ≥2 peripheral neuropathy according to the Common Toxicity Criteria for Adverse Events () v.5.0.
  4. Significant medical, neuro-psychiatric, or surgical condition, currently uncontrolled by treatment, which, in the principal investigator's opinion, may interfere with completion of the study.
  5. Any to pelvic irradiation as evaluated by the investigator.
  6. Known reactions to the study drugs or to any , premedications or non- medicinal products or concomitant medications.
  7. Any investigational anti-cancer therapy other than the protocol specified therapies (participation in other prospective studies which do not imply any specific intervention may be allowed after discussion with the Study Chair).
  8. Patients with a prior or concurrent whose natural history or treatment has the potential to interfere with the safety or efficacy assessment.
  9. (i.e., active) cardiovascular disease: cerebral vascular accident/stroke, myocardial infarction, unstable angina, congestive heart failure (grade III or IV as classified by the ), or serious cardiac arrhythmia requiring medication within the past 6 months.
  10. Complete dihydropyrimidine dehydrogenase (DPD) deficiency.
  11. Any previous treatment for rectal cancer.
  12. Use of brivudine, sorivudine or their chemically related analogues.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
230 participants (estimated)

Study arms

  • Experimental
    Conventional arm

    * SCRT (5 fractions of 5 Gy) * Surgery (according to the principle of TME) or watch \& wait * Optional adjuvant chemotherapy OR * LCCRT (25-28 fractions of 1.8-2.0 Gy each +/- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion fluorouracil or capecitabine) followed by * Surgery (according to the principles of TME) or watch \& wait, followed by * Optional adjuvant chemotherapy

    Radiation: Short course radiotherapy · Drug: Adjuvant chemotherapy (optional) · Procedure: Total mesorectal excision · Radiation: Long course chemoradiotherapy

  • Active comparator
    TNT arm

    Rapido regimen: * SCRT (5 fractions of 5 Gy) * Up to 18 weeks of oxaliplatin based chemotherapy (mFOLFOX6 or CAPOX) * Surgery (according to the principle of TME) or "watch \& wait" Or Rapido light regimen: * SCRT * Up to 12 weeks of oxaliplatin based chemotherapy * Surgery or "watch \& wait" Or OPRA with induction chemotherapy (INCT-CRT) regimen: * Up to 16 weeks of oxaliplatin-based chemotherapy * CRT (25-28 fractions of 1.8-2.0 Gy each +/- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion fluorouracil or capecitabine) * Surgery or "watch \& wait" Or OPRA with consolidation chemotherapy (CRT-CNCT) regimen: * CRT * Up to 16 weeks of oxaliplatin-based chemotherapy * Surgery or "watch \& wait"

    Procedure: Total mesorectal excision · Combination Product: Total neoadjuvant therapy

Interventions

  • RadiationShort course radiotherapy

    Patients will receive 5 daily fractions of radiotherapy. Each fraction will consist of 5 Gy for a total dose of 25 Gy.

  • DrugAdjuvant chemotherapy (optional)

    The choice of the adjuvant chemotherapy is to the investigator's discretion.

  • ProcedureTotal mesorectal excision

    Surgery must be performed according to the principles of total mesorectal excision. A "watch \& wait" approach is allowed for those subjects who have clinical complete response according to the local assessment.

  • Combination productTotal neoadjuvant therapy

    The choice of the TNT is left to the investigator's discretion. If RAPIDO: * SCRT (5 fractions of 5 Gy), followed by * Up to 18 weeks of oxaliplatin based chemotherapy (mFOLFOX6 or CAPOX) If RAPIDO light: * SCRT (5 fractions of 5 Gy), followed by * Up to 12 weeks of oxaliplatin based chemotherapy (mFOLFOX6 or CAPOX) If OPRA with induction chemotherapy: * Up to 16 weeks of oxaliplatin-based chemotherapy (mFOLFOX6 or CAPOX), followed by * CRT (25-28 fractions of 1.8-2.0 Gy each +/- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion fluorouracil or capecitabine) If OPRA with consolidation chemotherapy: * CRT (25-28 fractions of 1.8-2.0 Gy each +/- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion fluorouracil or capecitabine) followed by * Up to 16 weeks of oxaliplatin-based chemotherapy (mFOLFOX6 or CAPOX)

  • RadiationLong course chemoradiotherapy

    Patients will receive 25-28 fractions of 1.8-2.0 Gy each +/- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion fluorouracil or capecitabine

06

What researchers measure

Primary outcomes

  1. Overall survival

    Overall survival (OS) will be calculated from randomisation to death from any cause.

    Time frame: At 3 years after randomisation

  2. Progression-free survival

    Progression-free survival (PFS) will be calculated from randomisation to any of the following events: unresectable tumour due to local tumour progression, R2 resection of the primary tumour, loco-regional recurrence after an R0/R1 resection, distant metastases, or death from any cause.

    Time frame: At 3 years after randomisation

  3. Any grade peripheral sensory neuropathy

    Any grade peripheral sensory neuropathy as assessed by the investigator according to the NCI-CTCAE v5.0 will be analysed.

    Time frame: At 3 years after randomisation

  4. Grade ≥3 toxicities during treatment

    Grade ≥3 toxicities during treatment (i.e., from the 1st day of treatment until the EOT visit) as assessed by the investigator according to the NCI-CTCAE v5.0 will be analysed.

    Time frame: At 3 years after randomisation

07

Study locations

15 of 19 sites recruiting
08

References and documents

Publications

  • Saude-Conde R, Vandamme T, De Backer M, Martinive P, Covas A, Deleporte A, Dermine A, Forget F, Geboes K, Gilliaux Q, Gokburun Y, Gonne E, Joye I, Lecomte S, Liberale G, Lybaert W, Moretti L, Mortier L, Mupingu Mwanawa S, Puleo F, Saad ED, Sinapi I, Annemans L, Buyse M, Sclafani F. Efficacy and safety of short-course radiotherapy versus total neoadjuvant therapy in older rectal cancer patients: a randomised pragmatic trial (SHAPERS). ESMO Gastrointest Oncol. 2024 Jun 5;4:100067. doi: 10.1016/j.esmogo.2024.100067. eCollection 2024 Jun. PubMed 41648032 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Dec 2029, 70 months after the start.

Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 70 months is above that.

Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2023
First posted
Sep 25, 2023
StartActual
Feb 7, 2024
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2033
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06052332
Responsible party
Sponsor
First posted
Sep 25, 2023
Start date
Feb 7, 2024
Primary completion
Dec 2029 (estimated)
Completion
Dec 2033 (estimated)
Last update
Aug 3, 2026

Study contacts

Sophie Lepannetier, phD
Contact
ctsu.shapers@hubruxelles.be
+32 (0)2 541 34 56
Ikram El Idrissi
Contact
ctsu.shapers@hubruxelles.be
+32 (0)2 541 30 81
Francesco Sclafani
study chair · Jules Bordet Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion